IRIS Accounts Production v24.3.2.46 06310674 Board of Directors Board of Directors 1.8.23 31.7.24 31.7.24 false true false false false true false Fair value model Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh063106742023-07-31063106742024-07-31063106742023-08-012024-07-31063106742022-07-31063106742022-08-012023-07-31063106742023-07-3106310674ns15:EnglandWales2023-08-012024-07-3106310674ns14:PoundSterling2023-08-012024-07-3106310674ns10:Director12023-08-012024-07-3106310674ns10:Director22023-08-012024-07-3106310674ns10:PrivateLimitedCompanyLtd2023-08-012024-07-3106310674ns10:SmallEntities2023-08-012024-07-3106310674ns10:AuditExempt-NoAccountantsReport2023-08-012024-07-3106310674ns10:SmallCompaniesRegimeForDirectorsReport2023-08-012024-07-3106310674ns10:SmallCompaniesRegimeForAccounts2023-08-012024-07-3106310674ns10:FullAccounts2023-08-012024-07-310631067412023-08-012024-07-3106310674ns10:OrdinaryShareClass12023-08-012024-07-3106310674ns10:Director32023-08-012024-07-3106310674ns10:Director42023-08-012024-07-3106310674ns10:CompanySecretary12023-08-012024-07-3106310674ns10:RegisteredOffice2023-08-012024-07-3106310674ns5:CurrentFinancialInstruments2024-07-3106310674ns5:CurrentFinancialInstruments2023-07-3106310674ns5:ShareCapital2024-07-3106310674ns5:ShareCapital2023-07-3106310674ns5:SharePremium2024-07-3106310674ns5:SharePremium2023-07-3106310674ns5:FurtherSpecificReserve3ComponentTotalEquity2024-07-3106310674ns5:FurtherSpecificReserve3ComponentTotalEquity2023-07-3106310674ns5:RetainedEarningsAccumulatedLosses2024-07-3106310674ns5:RetainedEarningsAccumulatedLosses2023-07-3106310674ns5:NetGoodwill2023-08-012024-07-3106310674ns5:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3106310674ns5:PatentsTrademarksLicencesConcessionsSimilar2023-08-012024-07-3106310674ns5:PlantMachinery2023-08-012024-07-3106310674ns5:NetGoodwill2023-07-3106310674ns5:IntangibleAssetsOtherThanGoodwill2023-07-3106310674ns5:NetGoodwill2024-07-3106310674ns5:IntangibleAssetsOtherThanGoodwill2024-07-3106310674ns5:NetGoodwill2023-07-3106310674ns5:IntangibleAssetsOtherThanGoodwill2023-07-3106310674ns5:PlantMachinery2023-07-3106310674ns5:PlantMachinery2024-07-3106310674ns5:PlantMachinery2023-07-3106310674ns5:CostValuation2023-07-3106310674ns5:AdditionsToInvestments2024-07-3106310674ns5:DisposalsRepaymentsInvestments2024-07-3106310674ns5:RevaluationsIncreaseDecreaseInInvestments2024-07-3106310674ns5:CostValuation2024-07-3106310674ns5:WithinOneYearns5:CurrentFinancialInstruments2024-07-3106310674ns5:WithinOneYearns5:CurrentFinancialInstruments2023-07-3106310674ns10:OrdinaryShareClass12024-07-31
REGISTERED NUMBER: 06310674 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST JULY 2024

FOR

THE ORBITOFACIAL CLINIC LIMITED

THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST JULY 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


THE ORBITOFACIAL CLINIC LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31ST JULY 2024







DIRECTORS: Dr R Malhotra
Mrs Kavita Malhotra
G Malhotra
S Malhotra





SECRETARY: Mrs Kavita Malhotra





REGISTERED OFFICE: 1 Doughty Street
London
WC1N 2PH





REGISTERED NUMBER: 06310674 (England and Wales)






THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

BALANCE SHEET
31ST JULY 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 2 2
Tangible assets 5 37,866 44,386
Investments 6 306,570 481,867
Investment property 7 1,350,000 1,155,410
1,694,438 1,681,665

CURRENT ASSETS
Debtors 8 24,067 40,490
Cash at bank 112,507 23,101
136,574 63,591
CREDITORS
Amounts falling due within one year 9 78,618 219,795
NET CURRENT ASSETS/(LIABILITIES) 57,956 (156,204 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,752,394

1,525,461

PROVISIONS FOR LIABILITIES 85,000 35,000
NET ASSETS 1,667,394 1,490,461

CAPITAL AND RESERVES
Called up share capital 10 1,000 1,000
Share premium 24,750 24,750
Fair value reserve 290,402 145,812
Retained earnings 1,351,242 1,318,899
SHAREHOLDERS' FUNDS 1,667,394 1,490,461

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st July 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st July 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

BALANCE SHEET - continued
31ST JULY 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21st January 2025 and were signed on its behalf by:




Dr R Malhotra - Director



Mrs Kavita Malhotra - Director


THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST JULY 2024


1. STATUTORY INFORMATION

The Orbitofacial Clinic Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover represents net invoiced sales of services, excluding value added tax.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2008, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of nil years.

Patents and licences
Patents and licences cost is amortised over a period of 10 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 15% on reducing balance

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 3 ) .

THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST JULY 2024


4. INTANGIBLE FIXED ASSETS
Other
intangible
Goodwill assets Totals
£    £    £   
COST
At 1st August 2023
and 31st July 2024 150,000 6,885 156,885
AMORTISATION
At 1st August 2023
and 31st July 2024 149,999 6,884 156,883
NET BOOK VALUE
At 31st July 2024 1 1 2
At 31st July 2023 1 1 2

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1st August 2023 129,618
Additions 3,982
At 31st July 2024 133,600
DEPRECIATION
At 1st August 2023 85,232
Charge for year 10,502
At 31st July 2024 95,734
NET BOOK VALUE
At 31st July 2024 37,866
At 31st July 2023 44,386

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1st August 2023 481,867
Additions 82,330
Disposals (197,569 )
Revaluations (60,058 )
At 31st July 2024 306,570
NET BOOK VALUE
At 31st July 2024 306,570
At 31st July 2023 481,867

THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST JULY 2024


6. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 31st July 2024 is represented by:

Other
investments
£   
Valuation in 2020 12,392
Valuation in 2021 96,792
Valuation in 2022 (76,747 )
Valuation in 2023 23,430
Valuation in 2024 (60,058 )
Cost 310,761
306,570

7. INVESTMENT PROPERTY

Fair value of the investment property was £1,350,000 at 31st July 2024.

Fair value at 31st July 2024 is represented by:
£   
Valuation in 2016 39,606
Valuation in 2018 20,263
Valuation in 2021 111,936
Valuation in 2024 194,590
Cost 983,605
1,350,000

8. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 12,967 22,515
Other debtors 11,100 17,975
24,067 40,490

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security 44,329 44,620
Other creditors 34,289 175,175
78,618 219,795

10. CALLED UP SHARE CAPITAL

Allotted and issued:
Number: Class: Nominal 2024 2023
value: £    £   
1,000 Share capital 1 £1 1,000 1,000

THE ORBITOFACIAL CLINIC LIMITED (REGISTERED NUMBER: 06310674)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST JULY 2024


11. ULTIMATE CONTROLLING PARTY



The company was under the control of the directors throughout the year by virtue of them owning the majority of the issued share capital.